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ABSTRACT 
Objectives: The objective of this study was to determine the prevalence of atrial fibrillation 
(AF) in a tertiary care centre, to describe the comorbidity profile of hospitalised patients with 
AF, and to evaluate the appropriateness of their maintenance antithrombotic management. 
Methods: In a cross-sectional, descriptive study, all consenting hospitalised patients from 36 
wards in a University hospital (excluding critical care units, psychiatric, maternity and 
paediatric wards) received an ECG on a single day. Also their charts were reviewed for key 
demographic and clinical data. For patients with AF, all factors and comorbidities comprising 
thromboembolic (CHA2DS2-VASc) and bleeding risk (HAS-BLED) were listed. The 
appropriateness of long-term anticoagulant therapy was assessed according to the 2010 
international guidelines [CHA2DS2-VASc score 0 = aspirin or no antithrombotic treatment; 1= 
aspirin or oral anticoagulant treatment (OAC); ≥2=OAC]. The response rate was 79.7%, that 
is, an ECG was performed in 636 of 812 eligible hospitalised patients. 
Results: AF was present on ECG in 58 patients reflecting a 9.1% hospital point prevalence 
(95% CI 6.9% to 11.3%). Of the remaining 587 participants, 49 had a history of AF. Hence, 
107 AF cases were identified, yielding a total prevalence of 16.8% (95% CI 13.9% to 19.7%). 
Patients with AF were detected in every hospital zone, with highest prevalence rates in zone 
‘thorax’ [29.3% (95% CI 22.2% to 36.4%)] and ‘internal medicine’ [21.7% (95% CI 14.8% to 
28.6%)]. Patients with AF were older than patients without AF (78.7±10.3 years versus 
62.7±15.9 years; p<0.001). The most common associated comorbidities were hypertension 
(63.6%) and valvular heart disease (58.9%). Most patients with AF were at high risk for stroke 
(CHA2DS2-VASc-score ≥2 in 92.5%). Overall, only 51.3% of all patients did receive 
appropriate anticoagulant long-term management, while 31% were undertreated and 17.7% 
were possibly overtreated. 
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Conclusions: This hospital-based study revealed high AF prevalence rates (16.8%). Patients 
with AF were present in all hospital zones and almost all patients were at high risk for stroke. 
Anticoagulation management was likely inappropriate in 48.7%, indicating the need for better 
guideline implementation initiatives to guarantee hospital-wide optimised care for patients with 
AF.  
KEY WORDS 
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KEY MESSAGES 
What is already known on this subject? 
Atrial fibrillation (AF) is known as an evolving epidemic, however, no quantitative data exist 
on the overall prevalence of AF and its distribution in a hospital setting across all wards. It can 
be anticipated that the prevalence of AF in a hospital setting, with likely older patients who 
have more comorbidities, is higher compared with the community.  
What might this study add? 
This ECG-based evaluation of nearly the whole patient population in a tertiary care centre on a 
single day revealed a high point prevalence of 9.1% and an overall prevalence of 16.8%. 
Patients with AF were present in all hospital zones, and almost all patients with AF were at high 
risk for stroke (CHA2DS2-VASc-score≥2). Only 51.3% of all patients did receive anticoagulant 
long-term management conforming with the European Society of Cardiology (ESC) guidelines, 
while 31% were undertreated and 17.7% were possibly overtreated.  
How might this impact on clinical practice? 
The findings of this study illustrate that hospital-wide support to deliver optimal guideline-
based treatment to patients with AF is needed, especially in non-cardiac wards. Early 
recognition of AF, management to prevent stroke and other AF-related morbidity, management 
of underlying diseases, proper measures perioperatively or during intercurring events, and 
proper follow-up are all growing challenges. 
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INTRODUCTION 
There is increasing evidence about the prevalence of atrial fibrillation (AF), highlighting 
the burden of AF as an evolving epidemic (1-9). At the end of the 20th century, the overall 
prevalence in the general population was reported to be around 1%-2%. Nowadays, overall 
prevalence numbers range from 2.3% to 3.4% (1;3;5;9). AF prevalence is strongly dependent 
on age, increasing from <0.5-1% at age 40-50 years to over 6-15% in adults 80 years or older 
(3;8). Moreover, this population will further increase in the future as society ages and due to 
accumulation of predisposing conditions (4-8).  
Preventive healthcare and optimal guideline-based treatment management are needed to 
reduce AF-associated morbidity, mortality, unplanned hospitalisations and emergency room 
visits (10). Since AF is correlated with significant morbidity, including increased risk of stroke 
and heart failure, it consequently has a major impact on healthcare systems (11-13). 
Interdisciplinary AF expert programmes, likely with strong involvement of specialised nurses 
and providing evidence-based care are suggested to improve implementing and adapting 
personalised AF management (10;14;15). Nurse-coordinated care leads to a higher relative 
efficacy with respect to prevention of cardiovascular mortality and hospitalisations (14). AF 
expert programmes can be organised to focus on patients with AF referred to the outpatient 
clinic and on hospitalised patients (10). Hence, concerning the last, knowing prevalence, 
characteristics and medication management will help to establish and refine the need and scope 
of such programmes.  
To our knowledge, no quantitative data exist on the overall prevalence of AF and its 
distribution in a whole hospital setting. Hospitalised patients are likely older and have more 
comorbidities. By consequence, it can be anticipated that AF prevalence in a hospital setting is 
higher compared with the community. Hospital-based epidemiology studies mainly reported on 
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cohorts from cardiology departments or a combination of primary care patients and those 
attending a hospital as inpatients or outpatients (16-20).  
The main aims of this study were to determine the point-prevalence of AF, that is, 
measured on a single day, in a tertiary care centre, and to gain insight in the profile of 
hospitalised patients with AF. We also wanted to evaluate the appropriateness of the 
maintenance of antithrombotic management of the hospitalised patients with AF since 
antithrombotic therapy has proven mortality reduction benefits but is also related to iatrogenic 
bleeding if used inappropriately (11). 
METHODS 
Study population 
A cross-sectional, descriptive ECG-based study was conducted at the University 
Hospitals Leuven, Belgium on Tuesday 13 March 2012. The study covered 36 wards situated 
in seven different hospital zones: thorax (nine wards); internal medicine (seven wards); 
abdomen (seven wards); oncology (six wards); locomotor system (three wards); reproduction 
and growth (three wards); and sensory system (one ward). Psychiatric, maternity and paediatric 
wards were excluded from patient recruitment, as well as outpatient clinic services and critical 
care units. The latter units were excluded because AF often transiently occurs in critically ill 
patients. Patients hospitalised in the selected wards were included if they were ≥18 years old 
and had given verbal consent. Patients were also excluded if they were source-isolated or not 
Dutch-speaking. 
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Definitions 
Point prevalence was defined as ‘all patients diagnosed with AF on ECG at the time of 
measurement’. Overall prevalence was defined as ‘all patients diagnosed with AF on ECG 
and/or known with AF as evidenced from their medical history’. 
Procedure 
The day before the study, all hospitalised patients of the 36 eligible wards received a 
brochure with information about AF and the planned study. At the day of measurement and 
after obtaining verbal informed consent, a resting six-lead body surface ECG (leads I, II, III, 
aVL, aVF, aVR) was performed in all consenting patients. The ECG recordings were performed 
in a sitting or lying position, and were stored digitally. The full data collection was done within 
an 8 h period. Subsequently, AF prevalence was determined through analysis of all stored ECG 
traces by a certified cardiologist and clinical nurse specialist. Traces showing atrial flutter were 
also included and classified under ‘AF’, since in essence both arrhythmias are very similar 
concerning risk factors, consequences and management (21).  
Variables and measurement  
Full demographic and clinical data of patients with AF were retrieved from hospital 
records, while a smaller dataset was compiled for all participating patients. Demographic 
variables included gender, age, weight, height and the calculated body mass index. Belgian 
population data from the Belgian Federal Public Service Economy were used for age 
comparison. The type of AF (first diagnosed; paroxysmal; persistent; permanent) was based on 
the definitions of the European Society of Cardiology guidelines for the management of AF 
(11). For patients with AF, all risk factors and comorbidities comprising the thromboembolic 
risk score ‘CHA2DS2VASc’ [Congestive heart failure/LV dysfunction (EF ≤40%); 
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Hypertension (defined as systolic blood pressure ≥140mmHg); Age ≥75; Diabetes mellitus; 
Stroke/Transient Ischaemic Attack (TIA); Vascular disease, Age 65-74, Sex category (female 
gender)] and bleeding risk score ‘HAS-BLED’ [Hypertension (defined as systolic blood 
pressure >160mmHg); Abnormal renal and liver function; Stroke; Bleeding tendency or 
predisposition; Labile INRs (if taking Vitamin K Antagonists); Elderly (age>65); Drugs 
(concomitant aspirin, NSAID) or alcohol abuse or excess (>4/day)] were listed. Congestive 
heart failure was defined as heart failure with reduced EF (≤40%) or patients with recent 
decompensated heart failure requiring hospitalisation, irrespective of EF (12). Vascular disease 
was defined as patients with a history of ischaemic heart disease, complex aortic plaque, and 
peripheral arterial disease (PAD), including prior revascularisation, amputation due to PAD, or 
angiographic evidence of PAD. Patients with abnormal renal function were those with a history 
of acute or chronic kidney disease and a serum creatinine of ≥2.26 mg/dL, chronic dialysis or 
after kidney transplantation. Other comorbidities listed were ‘valvular heart disease’ (defined 
as any mitral or aortic valvular disease graded on echocardiography as ≥2/4 for regurgitation or 
≥ moderate for stenosis), ‘chronic obstructive pulmonary disease’ and a history of thyroid 
disease.  
The CHA2DS2-VASc-score was used to assess the appropriateness of anticoagulant 
therapy according to the international guidelines (11). As the study was conducted before 
publication of the 2012 focused update, the 2010 guidelines were used (12). Based on these 
recommendations, appropriate treatment for patients at low-risk for thromboembolic 
complications (CHA2DS2VASc=0) is no antithrombotic treatment or aspirin treatment, for 
patients with intermediate-risk (CHA2DS2VASc=1) it is aspirin or oral anticoagulation (OAC) 
treatment, and for high-risk patients (CHA2DS2VASc≥2) OAC treatment is indicated. Drugs 
prescribed as maintenance therapy including oral OAC therapy, platelet inhibitors, rate and 
rhythm control therapy were all recorded. 
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Statistical analysis 
Descriptive statistics for continuous data included mean and SD for normally distributed 
data, and median and IQR (Q1-Q3) for non-normally distributed data. Categorical data are 
presented as absolute frequencies and percentages. Logistic regression was used to correct for 
age in testing gender differences. Differences were tested with two-tailed t tests and ² tests. P 
values <0.05 were considered statistically significant. All analyses were performed using SPSS 
version 21.0. 
Patient anonymity was guaranteed and the data were only used for the present study. 
RESULTS 
AF prevalence 
The 36 included hospital wards comprised a total of 991 beds. At the day of 
measurement, 887 (89.5%) beds were occupied (figure 1). Seventy-five (8.5%) patients had 
exclusion criteria (age, language, isolation), leading to 812 eligible patients, 66 (8.1%) of which 
refused participation (reasons: ‘pain’, ‘fatigue’, ‘on telemetry’, ‘already ECG taken’ or ‘no 
consent’ without specific reason); 21 (2.6%) were not able to give permission; and 78 (9.6%) 
were absent after three ward visits. Hence, 647 patients participated (response rate =79.7%). 
Non-assessable ECGs were recorded in 11 participants, leading to a study population of 636 
patients. 
AF and atrial flutter were detected in 52 and 6 patients, respectively, reflecting a hospital 
point prevalence of 9.1% (95% CI 6.9% to 11.3%). Only one new diagnosis of AF was made 
among those patients. Of the remaining 578 participants, 49 (8.5%) had a medical history of 
AF based on chart review. Hence, 107 AF cases were identified, yielding a total prevalence of 
16.8% (95% CI 13.9% to 19.7%).  
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Patients with AF were detected in every hospital zone, with prevalence rates of 29.3% 
(95% CI 22.2% to 36.4%) in zone ‘thorax’; 21.7% (95% CI 14.8% to 28.6%) in ‘internal 
medicine’; 11.6% (95% CI 5.2% to 18%) in ‘oncology’; 7.6% (95% CI 3.1% to 12.1%) in 
‘abdomen’, 7.5% (95% CI 0.4% to 14.6%) in ‘reproduction and growth’; and 5.8% (95% CI 
0% to 12.1%) in ‘locomotor system’. In zone ‘sensory system’ a prevalence of 33.3% (95% CI 
2.3% to 63.7%) was measured, but it only concerned three out of nine patients. Almost half of 
the patients with AF were hospitalised in zone ‘thorax’ (43%) followed by ‘internal medicine’ 
(28%), ‘oncology’ (10.3%) and ‘abdomen’ (9.3%). 
Figure 1   Flow diagram showing patient recruitment and analysis, leading to estimates of AF   
                  point prevalence and AF prevalence. 
 
 
IC, informed consent; AF, atrial fibrillation 
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Characteristics of patients with AF  
Hospitalised patients with AF were significantly older than patients without AF 
(78.7±10.3 years vs 62.7±15.9 years; p<0.001) (table 1). Most patients with AF, 72.9%, were 
75 years or older. AF prevalence was slightly higher in men (19.1%) than in women (14.3%), 
which was statistically significant when corrected for age (p=0.031; OR=1.678; 95% CI 1.049 
to 2.684). 
Among patients with AF, the most common type was permanent AF (48.6%), followed 
by paroxysmal (24.3%) and persistent AF (20.6%). Only six patients (5.6%) had a single 
episode of AF (one=new; five=known from before). Of patients with atrial flutter on the index 
ECG, only one patient did not have a history of AF.  
Table 1   Characteristics of hospitalised patients with and without atrial fibrillation 
Characteristics Atrial fibrillation 
(n=107) 
No atrial fibrillation 
(n=529) 
p Value 
Age (years) (mean, ± SD) 78.7 (±10.3) 62.7 (±15.9) < 0.001 
Gender    
Women (%) 43 (40.2) 258 (48.8) 0.105 
Height (cm) (mean, ± SD) 168 (9.6) 168 (9.6) 0.849 
Weight (kg) (mean, ± SD) 72.8 (14.4) 72.0 (16.3) 0.625 
BMI (kg/m²) (mean, ± SD) 25,8 (4.6) 25.4 (5.1) 0.445 
BMI > 25 (%) 58 (54.2) 245 (46.3) 0.160 
BMI > 30 (%) 19 (17.8) 88 (16.6) 0.809 
Distribution per hospital zone    
Thorax (%) 46 (43) 111 (21) <0.05 
Internal medicine (%) 30 (28) 108 (20.4)  
Oncology (%) 11 (10.3) 84 (15.9)  
Abdomen (%) 10 (9.3) 122 (23.1)  
Reproduction and growth (%) 4 (3.7) 49 (9.3)  
Loco motor system (%) 3 (2.8) 49 (9.3)  
Sensory system (%) 3 (2.8) 6 (1.1)  
Type of AF     
First diagnosed AF (%) 6 (5.6)   
Paroxysmal AF (%) 26 (24.3)   
Persistent AF (%) 22 (20.6)   
Permanent AF (%) 52 (48.6)   
Atrial flutter* 1 (0.9)   
*One patient was only known with atrial flutter.  
AF, atrial fibrillation; BMI, body mass index. 
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Age distribution of patients with AF 
Figure 2 depicts AF prevalence by age group, showing increasing prevalence with age. 
AF prevalence was 13% in age stratum 70-74 years, nearly tripled to 37.3% in those aged 80-
84 years, and was >50% in nonagenarians. 
Figure 3 compares the age distributions of all patients in our study, of those with AF, 
and of the general Belgian population [Status: 1 January 2012; Statistics Bureau Belgium, 
Department Population]. The hospital population in this tertiary care setting is prominently 
older compared with the Belgian population. Moreover, the distribution of hospitalised patients 
with AF is shifted towards the oldest age-groups. 
Figure 2   Prevalence of atrial fibrillation (AF) by age group in a study population of 363  
                  hospitalised patients.   
 
IC, informed consent; AF, atrial fibrillation 
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Figure 3   Age distribution of different populations. 
 
AF, atrial fibrillation 
Comorbidities of patients with AF  
The most common associated comorbidities in patients with AF (figure 4) were 
hypertension (63.6%), valvular heart disease (58.9%) (electronic supplementary file 1), 
overweight (body mass index ≥25; 54.2%), kidney disease (46.7%; mostly chronic renal 
impairment), vascular disease (41.1%), congestive heart failure (32.7%) and diabetes (25.2%). 
A stroke history was reported in 14% and 7.5% had a history of a transient ischaemic attack. 
No significant differences in comorbidity profile were found between men and women. 
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Figure 4   Distribution of comorbidities in patients with atrial fibrillation (AF).                
 
BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, 
diabetes mellitus; HT, hypertension; KD, kidney disease; LD, liver disease; TD, thyroid disease; TIA, transient 
ischaemic attack; VD, vascular disease; VHD, valvular heart disease. 
 
Stroke risk factors and medication strategy 
Table 2 summarises stroke and bleeding risk profiles of patients with AF. The mean 
CHA2DS2-VASc-score was 4.1±1.7. Only 2 (1.9%) patients had a low risk 
(CHA2DS2VASc=0), 6 (5.6%) an intermediate risk (CHA2DS2VASc=1), and 99 (92.5%) a high 
risk (CHA2DS2VASc≥2) for stroke. The mean HAS-BLED score was 2.5±1.1 and 52% had a 
high bleeding risk (HAS-BLED≥3).  
In table 3 the anticoagulation regimen of patients with AF is plotted versus CHA2DS2-
VASc-score. One of the two patients with low risk for stroke was possibly overtreated by 
receiving anticoagulation therapy (AC). All but one patient with intermediate risk for stroke 
(n=5; 83.5%) received appropriate treatment [aspirin (n=1; 16.5%) or AC (n=4; 67%)]. In the 
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group with high risk for stroke 49 patients (49.5%) received appropriate long-term AC; 32 
(32.4%) were undertreated with aspirin therapy alone (n=16), double anti-platelet therapy (n=8) 
or no AC (n=8); and 18 (18.1%) were possibly overtreated with a combination of anticoagulants 
and anti-platelet agents. Of the 32 undertreated patients with high risk for stroke, 9 were 
hospitalised in zone internal medicine, 4 in abdomen, 3 in oncology and 16 in thorax, while 
only 4 were hospitalised in a non-surgical cardiovascular ward.  
Overall, only half of the hospitalised patients with AF (n=55; 51.3%) did receive an 
appropriate AC, while nearly a third (n=33;31%) were undertreated and a fifth (n=19; 17.7%) 
were possibly overtreated. Of all patients receiving AC (n=72), 56 patients were on OAC. 
Within the group of patients receiving OAC (n=56), 1 was treated with rivaroxaban (1.8%), 6 
with dabigatran (10.7%) and 49 took a vitamin K antagonist (87.5%).  
Reasons for not providing AC to patients at moderate to high risk for stroke were: ‘fall 
risk’ (n=6; 18.2%); ‘postoperative AF’ (n=5; 15.2%); ‘history of bleeding’ (n=4; 12.5%); 
‘palliative care’ (n=3; 9.1%); ‘patient refusal’ (n=3; 9.1%); ‘non-adherence’ (n=3; 9.1%); ‘age’ 
(n=2; 6.1%); ‘haemophilia B’ (n=1; 3.0%); ‘thrombopenia’ (n=1; 3.0%) and ‘Hydrea therapy 
for thrombocytosis’ (n=1; 3.0%). Sometimes more than one reason was given, while in 10 
patients (30.3%) no reasons were found. A valuable reason for possible overtreatment was 
found in 12 patients (63.2%) [‘coronary disease’ (n=9; 47.4%); ‘endoprosthesis’ (n=3; 15.8%)], 
while reasons were unclear or invalid in 7 patients (36.8%) [‘reason unclear’ (n=3; 15.8%), 
‘valve replacement’ (n=2; 10.5%); ‘pulmonary embolism’ (n=2; 10.5%)]. 
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Table 2   Stroke and bleeding risk factors and other co-morbidities 
Stroke risk factors AF (n=107) Bleeding risk factors AF (n=107) 
Congestive heart failure/LV dysfunction (%) 35 (32.7) Hypertension (%)* 57 (53.3) 
LV EF ≤ 40% (%)** ≥ 21 (19.6) Abnormal renal function (%) 50 (46.7) 
Hypertension (%)*** 68 (63.6) Chronic kidney disease (%) 37 (34.6) 
      Age ≥75 (%) 78 (72.9) Acute kidney disease (%) 10 (9.3) 
Diabetes mellitus (%) 27 (25.2) Kidney transplantation (%) 3 (2.8) 
Stroke / TIA  23 (21.5) Abnormal liver function (%) 9 (8.4) 
Stroke (%) 15 (14) Stroke (%) 15 (14) 
Transient ischaemic attack (TIA) (%) 8 (7.5) Bleeding tendency or predisposition (%) 13 (12.1) 
Vascular disease 44 (41.1) Labile INRs (%) (if taking VKA only) 4 (3.7%) 
Ischaemic heart disease (%) 40 (37.4) Elderly, for example, age > 65 years (%) 94 (87.9) 
Age 65-74(%) 18 (16.8) Drugs (concomitant aspirin, NSAID) (%) 40 (37.4) 
Sex category (female gender) 43 (40.2) Alcohol abuse or excess (>4/day) (%) 7 (6.5) 
CHADS2 score (mean, ± SD) 2.4 (±1.3)      HAS-BLED score (mean, ± SD) 2.5 (±1.1) 
CHADS2 score (median, IQR) 2.0 (1.0-3.0)      HAS-BLED score (median, IQR) 3.0 (2.0–3.0) 
CHA2DS2VASc score (mean, ± SD) 4.1 (±1.7) 0 (%) 3 (2.8) 
CHA2DS2VASc score (median, IQR) 4.0 (3.0–5.0) 1 (%) 19 (17.8) 
0 (%) 2 (1.9) 2 (%) 29 (27.1) 
1 (%) 6 (5.6) 3 (%) 36 (33.6) 
2 (%) 11 (10.3) 4 (%) 17 (15.9) 
3 (%) 20 (18.7) 5 (%) 3 (2.8) 
4 (%) 24 (22.4) ≥6 (%) 0 (0.0) 
5 (%) 23 (21.5) Other co-morbidities  
6 (%) 15 (14.0) Valvular heart disease (%) 63 (58.9) 
7 (%) 4 (3.7) Chronic obstructive pulmonary disease (%) 14 (13.1) 
8 (%) 1 (0.9) History of thyroid disease (%) 11 (10.3) 
9 (%) 1 (0.9)   
*Hypertension defined as systolic blood pressure >160mmHg. 
**Eleven missing values. 
*** Hypertension defined as systolic blood pressure ≥140mmHg. 
AF, atrial fibrillation; BMI, body mass index; TIA, transient ischaemic attack; VKA, vitamin K antagonist. 
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DISCUSSION 
The purpose of this cross-sectional study was to assess the point and overall prevalence 
of AF in a hospitalised population. We also investigated the appropriateness of patients’ longer-
term anticoagulant treatment. The main finding was a remarkable high point and overall 
prevalence of AF, with almost all patients with AF being classified as high-risk patients for 
stroke. Unfortunately, only half of them were strictly treated in conformance with the 
anticoagulation guidelines.  
An AF point prevalence of 9.1% and especially an overall prevalence of 16.8% in a 
hospital population is considerably higher than the current estimates of the overall prevalence 
of 2.3%-3.4% in the general population (1;3;5;9;22). There have been prior reports on AF 
prevalence in hospitalised patients but none of these were measured in a hospital-wide setting: 
some were restricted to only cardiovascular patients or those with acute medical admissions 
(with rates ranging, respectively, between 8-14% (16;19) and 2.8-10.4% (17;18)), while others 
combined inpatients and outpatients (20). Our study included patients hospitalised in all 
hospital zones (including those without cardiovascular expertise in the medical team), and 
surprisingly detected patients with AF in every zone. 
As expected, AF prevalence in our study steeply increased with age (3;5;6;22) and was 
most prevalent in the 75+ years age group as is also seen in the general population (2;22). 
However, the age-stratified prevalence was also substantially higher than in the general 
population, with rates of 12% in patients aged 65-69 years to 37% in patients aged 80-84 years 
(compared with 5% to 15%, respectively, in community-based studies (4;8;9;20)). This 
indicates that the higher AF prevalence in a hospital population is due to a higher average age 
than the general population (as was shown in figure 3), and to a higher prevalence of AF-
promoting comorbidities. Hospital populations are known to contain patients with more than 
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one comorbid disease, further increasing with age (23). In the present study, most AF-related 
comorbidities were in line with prior insights: hypertension is by far the most common AF-
related condition. Furthermore, also valvular disease, vascular disease, congestive heart failure 
and diabetes were common (figure 4), in line with prior findings (3;4;9;23;24). However, we 
found a higher prevalence of chronic kidney disease (35%) and thrombo-embolic antecedents 
(14%), compared with 8-17% and 6-8%, respectively, in other studies (4;24). A possible 
explanation again could be the older age distribution in our hospital population as both 
conditions are clearly related to ageing (23). 
The present study recorded suboptimal pharmacological antithrombotic treatment of  
patients with AF when evaluated based on their CHA2DS2-VASc-score, confirming the gap 
between evidence-based care and real-life practice (16;25). Hospitalised patients have a high 
risk for stroke (93% in our sample had a CHA2DS2-VASc-score≥2). Most overtreatment 
(63.2%) could be explained by a reasonable explanation (like a recent acute coronary 
syndrome), while underuse could not be explained in 33.3%. Our study confirms observations 
from the Euro Heart Survey that more patients are undertreated than overtreated (25). Another 
study in stable outpatients with AF with high risk for stroke found that 41% was undertreated, 
which is even higher than in the hospitalised patients with AF of the present study (31%) (26). 
Undertreatment of high-risk patients is still a major problem in the implementation of guideline-
recommended antithrombotic management in AF. The Euro Heart Survey authors also 
demonstrated that undertreatment leads to adverse outcomes much more commonly than 
overtreatment. Our study found that 87.5% of the undertreated high-risk patients were 
hospitalised in non-cardiac wards, indicating that non-adherence to the guidelines is a bigger 
problem in those wards than in non-surgical cardiac wards. The reasons for undertreatment in 
the present study indicate that physicians’ clinical judgement incorporates factors beyond those 
included in the CHA2DS2-VASc-score, like ‘fall risk’, ‘postoperative AF’, ‘palliative care’, 
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‘non-adherence’, ‘high age’ or ‘co-morbidity’ that are considered as contraindications for OAC. 
According to Nieuwlaat et al (27) other possible factors contributing to this undertreatment 
could be knowledge deficit of the guidelines; distraction by other medical problems, no 
management by an AF specialised physician or the absence of an OAC monitoring outpatient 
clinic. All underscore the need for a more structured and hospital-wide decision support system.  
Indeed, the above-described findings of our study illustrate that hospital-wide support 
to deliver optimal guideline-based treatment to patients with AF is needed, especially in non-
cardiac wards. Education on stroke prevention for patients with AF should focus on the 
importance of tailoring antithrombotic therapy according to patient’s risk profile. Extra 
improvement might be achieved by integrating stroke risk stratification guidelines in supporting 
information technology (27) with automatic alerts that highlight patients with AF. This can 
remind physicians to evaluate the risk profile and antithrombotic therapy, even if patients are 
hospitalised for other reasons. Structural support by interdisciplinary AF expert programmes 
relying on specialised nurses may be very important for hospitals to guarantee hospital-wide 
optimised care for patients with AF as comorbidity (10;14;15). This is the case in at least 16% 
of the hospital population. This prevalence may further increase, due to the aging population 
and increasing complexity of hospitalised patients. Early recognition of AF, management to 
prevent stroke and other AF-related morbidity, management of underlying diseases, proper 
measures perioperatively or during intercurring events, and proper follow-up will become 
increasing challenges. There is growing evidence and general acceptance for similar hospital-
wide services for other conditions, like diabetes, decubitus, stroke and geriatric support (28-
31). The AF prevalence rate that we recorded is even higher than the reported 11% prevalence 
of diabetes among hospital inpatients (28), underscoring the need for similar services for 
patients with AF.  
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LIMITATIONS 
First, although already high AF prevalence rates were measured, we still may have 
underestimated the real prevalence given a response rate of 79.3%, the reliance on chart review 
for documentation of a known history of AF, and the exclusion of patients hospitalised in 
critical care units. Literature reports of AF prevalence in non-cardiac surgical intensive care 
units range from 5% to 10%, in medical intensive care units from 6% to 26% and after cardiac 
surgery from 10% to 65% (32). Second, as the present study only collected data at one single 
tertiary care centre, the generalisability of the results to other hospital settings is unclear. A 
tertiary hospital might see more patients with AF, as hospitalised patients might have more 
comorbidities and more severe illnesses leading to AF compared with other hospitals. 
Furthermore, the particular position of a tertiary hospital within healthcare environment and the 
structure of the hospital itself might also influence the prevalence of AF. As the prevalence on 
a single day might vary over time, this can also comprise the generalisability, although the large 
sample size makes the assessment relatively robust. Third, guideline adherence to rate and 
rhythm control were not explored in the present study. Finally, this study did not evaluate the 
comorbidity profile in the large group of patients without AF. Therefore, differences with the 
hospital population with AF could not be evaluated.  
 
      
 
Table 3   Anticoagulant treatment strategy in hospitalised patients with AF per specialty, according to CHA2DS2-VASc-score. 
Zone Ward specialty 
 
 
Surgical 
specialty 
 
 
All 
patients 
 
 
Patients 
with AF 
CHA2DS2-VASc-score*   
0 (n=2) 1 (n=6) ≥ 2 (n=99) 
A O U A U A O U O 
Thorax             
 
Respiratory medicine  
   23 4     
1† 
2‡ 1§  
1†: Postoperative AF (12h postoperative) 
1‡: Palliative care 
1‡: No reason + coronary disease   
  Thoracic surgery  x  15 1     1¶   1¶: Patient refuses to take VitK  
  Respiratory medicine  x  15 2  1§    1**   1§: Pulmonary embolism 
 Respiratory medicine     11 1     1¶   1¶: Fall risk  
 
Cardiovascular medicine 
   15 1     1‡   
1‡: Hydrea therapy for thrombocytosis + coronary 
disease  
 Cardiovascular medicine    20 8   1¶   6** 1†† 1¶: Haemophilia B 1††: Coronary disease 
 
Cardiovascular surgery  
x  17 8     2† 4** 
1‡‡ 
1§§ 2†:No reason  
1‡‡: Stent superficial femoral artery. 
1§§: Endoprosthesis  
 
Cardiac surgery 
x  20 13     
4† 
1‡ 1** 
1¶¶ 
6‡‡ 
2†: Postoperative AF (≥72 h postoperative) + coronary 
disease 
1†: No reason + valve replacement  
1†:  Postoperative AF (≥72 h postoperative) + valve 
replacement  
1‡: No reason + coronary disease  
1¶¶: Endoprosthesis + coronary disease  
2‡‡: Valve replacement +coronary 
disease  
2‡‡: Valve replacement  
2‡‡: Coronary disease  
 
 
Cardiovascular medicine  
x  21 8     
2‡ 
1† 4** 1‡‡ 
1‡: Fall risk + coronary disease 
1‡: Non-adherence + history of bleeding  
1†: Fall risk 1‡‡: Coronary disease 
Internal medicine             
 Rheumatology/ Endocrinology    22 0          
 
Geriatric medicine  
   22 8     3† 5**  
1†: Patient refuses to take VitK + non-adherence 
1†: Palliative care 
1†: No reason  
 
Geriatric medicine 
   21 7     
2† 
1‡ 
1** 
1 (d) 
1‡‡ 
1¶¶ 
1†: History of bleeding + fall risk  
1†: Age + fall risk 
1‡: Patient refuses to take VitK + coronary disease 
1‡‡: Coronary disease  
1¶¶: Reason unclear 
 Neurology    17 0          
 Stroke-unit    14 2     1¶ 1 (d)  1¶: History of bleeding  
 General internal medicine    24 2     1¶ 1**  1¶: Fall risk + palliative care  
 
Geriatric medicine 
   18 11     1¶ 
5** 
3§ 
1 (d) 1‡‡ 1¶: Age` 1‡‡: Coronary disease 
Abdomen             
 
Kidney / liver transplantation 
x  20 2     
1¶ 
1†   
1¶: Postoperative AF (≥72 h postoperative)  
1†: No reason  
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Nephrology 
   8 2     1‡  1¶¶ 
1‡: Non-adherence + history of bleeding    
       + coronary disease 1¶¶: Reason unclear 
 Gastroenterology    19 3    1† 1† 1**  1†: No reason  
 Abdominal surgery x  19 0          
 Abdominal surgery x  27 1    1**      
 
Gastroenterology/ hepatology/ abdominal 
surgery x  17 0          
 Hepatology     21 2    1§  1(d)    
Oncology             
 
Oncology  
   21 2      1§ 1¶¶  
1¶¶: Pulmonary embolism + palliative 
care 
 
Oncology  
   13 3     1¶ 
1** 
1§  1¶: No reason  
 Hematology    16 2 1¶    1¶   1¶: Thrombopenia  
 
Oncology surgery / Multidisciplinary 
breast centre  x  16 1      1**    
 Gastroenterology and Hepatology    18 3     1† 2(d)  1†: No reason  
 Hematology    11 0          
Locomotor system             
 Neurosurgery x  19 0          
 Traumatology x  15 2      2**    
 Plastic and reconstructive surgery x  18 1       1¶¶  1¶¶:Reason unclear 
Reproduction and growth             
 Urology x  11 0          
 Urology x   20 3    1§  1§ 1***  1***:  Coronary disease 
 Gynaecology x   23 1      1**    
Sensory sytem             
 Ear, Nose and Throat / Stomatology x  9 3    1**  2**    
Total 36 wards 17 636 107 1 1 1 5 32 49 18 33 19 
* Guideline recommendations:  
CHADSVASc =0    →   aspirin or no antithrombotic treatment. 
CHADSVASc =1    →   aspirin or oral anticoagulation. 
CHADSVASc ≥2    →   oral anticoagulation. 
† ASA; ‡ Double antiplatelet therapy; § LMWH.; ¶ No treatment; ** VitK; (d) Dabigatran. 
†† VitK + Clopidogrel. 
‡‡ VitK + ASA. 
¶¶ LMWH + ASA. 
***VitK + ASA + Clopidogrel. 
A, appropriate treatment; ASA, aspirin; O, possible overtreatment; OAC, oral anticoagulation; U, undertreatment; VitK, vitamin K antagonist. 
      
 
 
CONCLUSION 
 This ECG-based evaluation of nearly the whole patient population in a tertiary care 
centre on a single day revealed clearly high AF prevalence rates, with a point prevalence of 
9.1% and an overall prevalence of 16.8%. Patients with AF were present in all hospital zones, 
and almost all patients with AF were at high risk for stroke. Anticoagulation management was 
likely inappropriate in half of those. Overtreatment was often justifiable but undertreatment of 
high-risk patients is still a major problem, even in a hospital population. Our results highlight 
the need for new strategies to improve the implementation of guideline-recommended 
management to guarantee hospital-wide optimised care for patients with AF. Which structured 
support system(s) would best attain such goal requires further research. We hope that our 
observations stimulate such endeavours. 
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Supplementary appendix 1   Detailed echocardiographic data of atrial fibrillation patients with valvular heart disease. 
Valvular heart disease*  
Type of valve dysfunction Severity 
none 1/4  2/4  3/4  4/4  ≥2/4  
Mitral regurgitation                      
n (%) 
3 (4.8) 5 (7.9) 34 (54.0) 18 (28.6) 3 (4.8) 55 (87.3) 
Aortic regurgitation                      
n (%) 
22 (34.9) 15 (23.8) 20 (31.7) 5 (7.9) 1 (1.6) 26 (41.3) 
Tricuspid regurgitation                
n (%) 
5 (7.9) 9 (14.3) 21 (33.3) 22 (34.9) 6 (9.5) 49 (77.8) 
Pulmonary regurgitation            
n (%) 
20 (31.7) 35 (55.6) 7 (11.1) 1 (1.6) 0 8 (12.7) 
 none  mild moderate severe  ≥moderate 
Mitral stenosis                             
n (%) 
60 (95.2) / 2 (3.2) 1 (1.6) 0  1 (1.6) 
Aortic stenosis                            
n (%) 
45 (71.4) / 4 (6.3) 3 (4.8) 11 (17.5) 14 (22.2) 
Tricuspid stenosis                       
n (%) 
63 (100%) / 0 0 0 0 
Pulmonary stenosis                    
n (%) 
63 (100%) / 0 0 0 0 
 
Valve surgery None Aortic valve 
replacement 
Aortic and mitral 
valve replacement 
Mitral valve 
replacement 
Mitral valve and 
tricuspid valve plasty 
Mitral valve 
plasty 
n (%) 47 (74.6) 10 (15.9) 2 (3.2) 2 (3.2) 1 (1.6) 1 (1.6) 
*Defined as any mitral or aortic valvular disease graded on echocardiography as ≥2/4 for regurgitation or ≥ moderate for stenosis [n=63; 100%; mean 
age=79.6, SD=±2.3; In many patients (n=51;81%), there was concomitant tricuspid or pulmonary regurgitation.] 
